Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Mrvivo, New profile, one post, looks like Mr Sheedy trying to worm his way back in. Do us all a favour and do some homework.
I agree wholeheartedly.
FD/CEO and BoD reviewed finance and must have known the risks and factored it in and agreed to go ahead.
DYOR on skills that allowed this. It speaks for itself. I have lost all confidence and the pay haircut is insulting based on loss of value that has occurred.
SBTX roles: CEO, FD, a Capital market advisor apparently, non-executive chair, two Non executives dir. Ability to perform any governance has been shown lacking. One non exec has background in brewing, one has background in cell therapy. No clinical studies to drive uptake with 550 customers after two and a half years and marketing that seems dominated by company recommending itself. Skills and relevance must now be questioned and corrected with urgency to change the trajectory.
Head of formulation, Financial controller, Customer service manager. Others?
Dermatonics roles: founder/advisor (who sold the business so he could retire so earn questions here given extra £££ we are paying in 24/25 ), Financial controller, Manager, sales consultant, Others????
light on experience so obvious why deadlines seem unimportant and are essentially never hit.
PG, I think it's World Products. It's not global, but UK, Europe and USA via Amazon.
I think you are referring to the consumer study for Acne. It is due at any time, but it needs to be written. I am more interested in Dermatonocs sales, UMG forecasts, and Croda launch/forward sales circa June, from memory. These news items are directly related to money now, not months later. These will drive a massive re-rate.
CB resolution would also drive a re-rate for obvious reasons, but I think most of us are aware of why.
Elrico, haven't they signed up a global sales team for amazon global sales? Have we past another deadline for news update for axis?
I agree Leapfroggy Bekker is definitely a weak link and has done nothing in the 2 years since she was hired. I didn’t understand her appointment in the first place. She has no relevant transferable experience and is an unnecessary waste of a seat at the table. Needs to be replaced with someone who can deliver and has sector experience.
Leepfroggy, I suspect there will be a coming together of minds to work out the best strategy in the future with the Dermatonics staff, who have had some success with their own sales/marketing team. This must be one synergy that some people have overlooked.
About time we had a new set of Directors to reflect the need to take our products to the market. Now we have an agency to develop our online presence, I fail to see why we need Danielle Bekker whose CV looks pretty lightweight and failed to create sales for Axisbiotix.
Good results from l'Oreal today and of particular note "All Divisions grew with stellar performances from the Consumer Products and Dermatological Beauty Divisions" so the Consumer appetite is certainly there for quality ingredients and products.
https://www.loreal-finance.com/eng/news-release/first-quarter-2024-sales
Boardroom changes???????
Never known it so quiet, hopefully acne study out soon.
It’s ironic that I subscribed to this web site recently and after reading this article and considering opinion on the future of UK stocks (which pension funds have stopped investing in) and the future for Aim (down 50% since 2021) and the near impossibility of funding I have sold up most of my Aim holdings. When the overall direction is overwhelmingly down, it doesn’t make sense to me to continue trading on Aim. That there have only been 10 AIM IPOs so far this year tells me the market is broken. It costs around £200k in RNS etc just to stay on Aim. I’m still holding on SBTX (but not adding) and URAH (main market and recently raised twice at around the SP).
It is not specific to SBTX, but it provides details of the board's predicament. Some people may not appreciate it, but they will!
OPEN SOURCE
https://open.substack.com/pub/smallcompanychampion/p/londons-capital-conundrum?r=398wvs&utm_campaign=post&utm_medium=web&showWelcomeOnShare=true
Hello Martinu
I am not well versed in such matters either but the RNS implies a direct relationship between macquarie and the purchasers, I assume they agree a price between them.
'Long term shareholders, including Tyndall Investement Management who have invested in the Company since IPO, have agreed to purchase the shares directly from Macquarie Bank.'
Yes Madabout, there is something to be said for the facility to be almost halfway done in this timeframe. I’m pleased about it. I’d like to know how SA feels about it and if it influences his next moves on removing the company from the CLN which they have acknowledged the market reacted badly to. Well, I think we know it will have influenced things in that it will make it easier for SA to deal out of the agreement. I’ll look forward to asking about it at the next IMC presentation.
Why would Macquarie sell at the conversion price? They want an upside surely? The very large trade the other day was at 9p so they would have made 2.5p per share margin and Tyndall get a large block of shares to add to their already significant holding below market price. The good news is that the newly released shares now sit in long term holders hands and the facility is almost halfway done in under 3 months.
Nick, as someone who is not well versed in such matters, I was wondering about such questions. Are Macq able to transfer direct to, eg Tyndall ? (Recall, Tyndall weren't the only participator). If this direct transfer is possible, would Tyndall and others have wanted a price closer to 6.5p.
I know my input will not be appreciated as I am apparently a troll. If macquarie exercise their options and sell to Tyndall my understanding is they can do that 'off market' is that correct? If so the buys/sells are not anything to do with Macquarie. Also if all the large transactions are Macquarie selling to Tyndall why not the same price?
IMHO,
The 12 preferential clients would have formulated the lysate into their brands and will have produced the marketing and advertising for when Croda launches the ingredient. These cosmetic giants will compete to be first to market. We then can monitor the reception of the product, which I believe will be marketed very rapidly.
Once again, which part of the RNS last week do you not understand? The shares are converted by Macquarie and then bought by long term holders. Tyndall were specifically named which means this intent would have to be proven to the authorities before that statement could be released. Now you start to see the transfers coming through (and they may not all be on massive blocks) and you’re off scaremongering yet again. Time for the filter methinks.
Belgrano, i was aksed to so i will apologise for some of my comments to you the otherday. It was explained to me that you are not the devious crook i accused you of. I can see you are genuine with your misreading of specific events as you have done again today. Sorry for the abuse.
Al, you're wrong again! I explained it to you yesterday. These are the shares bought by Tyndall at a premium to what Macquarie converted at. Nice gig if you can get it. Apply logic, my friend.
Although I got abuse over my thoughts that stock would be offloaded, and made a strong case it most certainly does appear that I was correct. Another 2 million share sell just came through coupled with some other still hefty ones.
Or a CEO perhaps....
Quite right. We should not be spending money developing new scientific discoveries but monetarising our existing science and proving up what we have. The Dermatonics founder has said that the key to past and future growth is the scientific evidence behind the product. This is the reason Modi are investing heavily in marketing our products. We are better off investing in product development through a leading university rather than paying for a Scientific Officer.
I used to work in academia. Many academics are employed full-time at their universities but also maintain other commitments that are time-consuming, or have other commercial roles. It also depends upon how her university apportions her employment. Often external commitments, if they are linked to the subject you are employed within are classed as part of the 1/3 research requirement of the standard academic employment contract.